Introduction: Licensing as the Lifeblood of Biopharmaceutical Innovation In biopharmaceutical innovation the drug patent licensing agreement stands as the central, […]

A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent.

In the multi-trillion-dollar pharmaceutical industry, there’s an attic. It’s filled not with dust and forgotten relics, but with something far

Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred

When Pfizer launched atorvastatin (Lipitor) in 1997, it did not simply sell a cholesterol drug. It built, over the next

Introduction: The Allure of the Biotech Lottery: Beyond the Hype Scan the financial headlines on any given day, and you’re

In the spring of 2014, a small biotech called Idenix Pharmaceuticals held patents covering certain nucleotide analogue structures with antiviral

How Drug Patent LOE forecasting gives equipment suppliers a 24-month head start on their competitors Every year, branded pharmaceutical companies

The Question Nobody Answers Clearly Ask a pharmaceutical executive how long a drug patent lasts in Latin America and you